Vanda Pharmaceuticals (NASDAQ:VNDA) will post its quarterly earnings results after the market closes on Wednesday, November 7th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.04) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
VNDA stock opened at $20.21 on Tuesday. The company has a market capitalization of $1.07 billion, a PE ratio of -57.74 and a beta of 1.06. Vanda Pharmaceuticals has a twelve month low of $11.90 and a twelve month high of $23.50.
A number of brokerages recently commented on VNDA. BidaskClub lowered Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 1st. Stifel Nicolaus reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, October 31st. TheStreet upgraded Vanda Pharmaceuticals from a “c” rating to a “b-” rating in a report on Friday, October 26th. Citigroup lifted their price target on Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, October 16th. Finally, Zacks Investment Research upgraded Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price target on the stock in a report on Friday, October 12th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $26.86.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
See Also: What are the Benefits of Index Funds?